It was a positive week for the European Medicines Agency’s human medicines committee (CHMP), which recommended the approval ...
Ipsen’s new sponsored TikTok features the popular “Of course” trend and two social influencers, but with a rare disease twist ...
Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health ...
We’re in a frothy time,” acknowledges Alexandra Snyder, the head of R&D at Generate:Biomedicines. Generate is one of the ...
Cigna’s health services arm Evernorth said on Thursday that it plans to offer a cheaper copycat of AbbVie’s blockbuster drug ...
The FDA on Friday approved a label update on Biktarvy, Gilead’s blockbuster HIV drug, to include more data on the drug’s safety and efficacy for pregnant people with HIV. The additional data reflected ...
UCB is shaking up its leadership team “to better align with its commitment to growth and innovation, and to better address ...
Gilead reported sales of $6.6 billion, a 5% increase year-over-year, prompting Mizhuo analysts to write that the ...
AbbVie's effort to protect Humira's market share is getting expensive. On Friday, the company announced a 40% decline in the megablockbuster drug's US sales for the first quarter. While it managed to ...
RevOpsis Therapeutics secures $16.5M seed round: The San Carlos, CA-based biotech will use the funds to complete IND-enabling studies for its lead candidate, RO-104, for neovascular age-related ...
GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the ...
Sage Therapeutics is doubling down on the “blockbuster potential” of its postpartum depression drug Zurzuvae, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback